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Objective: The primary objective of this study was to compare knowledge and perceptions of
medical cannabis (MC) between pharmacy students who attended schools where MC was legal
and illegal.
Design: A nationwide anonymous survey regarding MC was distributed to pharmacy students.
The survey consisted of the following sections: (1) demographics and personal factors, (2)
knowledge assessment of indications and adverse effects of MC, and (3) perceptions
assessment.
Setting and participants: Equal numbers of pharmacy schools were selected and sent surveys
based on geographical regions, private versus public universities, and the state’s legal status of
MC for first through fourth-year pharmacy students to complete.
Outcome measures: Student knowledge of MC indications and adverse effects were treated as
quizzes. Median percentage correct and whether students passed the quizzes ( 70%) were
evaluated based on the state’s legal status. Students’ perceptions were similarly compared.
Results: A total of 629 students accessed the survey. Most students who completed the survey
attended pharmacy schools where MC was illegal (55%), were female (68%), and had
personally tried cannabis (53%). Overall, 91% of students believed that MC should be legalized
nationally. A low number of students correctly identify approved indications with 14.8% of
students in states with MC legalization scoring greater than 70% compared with 15.9% of
students in states without MC legalization (P ¼ 0.748). Similar findings were seen in the side
effects quiz with only 6.1% of students in states with legal MC scoring greater than 70%
compared with 7.4% of students where MC is illegal (P ¼ 0.569) There were minimal differ-
ences in students’ perceptions of MC based on the states’ legal status.
Conclusion: Our study continues to highlight that pharmacy students lack knowledge and
preparation to counsel and educate on MC. With increasing state legalizations, pharmacy
schools need to address this knowledge gap to ensure optimal patient care.
© 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Cannabis is the most commonly abused illicit substance
worldwide.1 Since California first legalized medical cannabis
(MC) in 1996, there has been a dramatic shift in the landscape
of MC in terms of availability as well as public opinion.2 As of
2019, 33 states and the District of Columbia have MC laws
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ion®. Published by Elsevier Istate with MC legally available.3 Public opinion has likewise
dramatically changed with a 2016 survey finding that 81% of
respondents favor legalization of cannabis for medical use.1
Although public opinion supports legalization for medical
use, there remains controversy regarding the safety and effi-
cacy of MC, and conflicts between state and federal law with
cannabis remaining a Schedule I controlled substance.1
Cannabis is a complex compound containing hundreds of
cannabinoids, flavonoids, and terpenoids.4 The cannabinoids
of greatest interest are delta-9-tetrahydrocannabinol (THC),
the primary psychoactive component, and cannabidiol (CBD).
Reports in the media and the Internet abound on the potential
benefits of THC and CBD; however, the evidence is conflicting
or lacking regarding their safety or efficacy. The National
Academies of Science published a comprehensive review ofnc. All rights reserved.
Key Points
Background:
 Over half of the U.S. population lives in an area
where medical cannabis (MC) is legal.
 Pharmacists are now playing an increasing role in
providing drug information on MC.
 Previous studies of pharmacy students conducted in
single states showed pharmacy students lack
knowledge of MC.
Findings:
 Pharmacy students continue to lack knowledge on
indications and adverse effects of MC. Minimal dif-
ferences in knowledge and perceptions were
exhibited based on state cannabis laws where phar-
macy students attended school.
 Over 80% of pharmacy students think MC is safe,
which mirrors public perceptions.
 Most pharmacy students support MC legalization,
and nearly all students feel instruction on MC should
be in pharmacy school curriculums.
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SCIENCE AND PRACTICEthe efficacy and safety of cannabis, which found conclusive or
substantial evidence that cannabis or cannabinoids are effec-
tive for the treatment of chronic pain, chemotherapy-induced
nausea and vomiting, and spasticity in multiple sclerosis.5
There are 2 Food and Drug Administrationeapproved pre-
scription medication formulations of THC (dronabinol and
nabilone) and 1 approved formulation of CBD (cannabidiol).6-8
Dronabinol and nabilone are both indicated for
chemotherapy-induced emesis in patients who have failed
other anti-emetic agents, whereas dronabinol is also approved
for anorexia in patients with acquired immunodeficiency
syndrome.7,8 The cannabidiol prescription formulation is
approved for the treatment of seizures associated with
Lennox-Gastaut syndrome or Dravet syndrome.6
Pharmacists are considered the most accessible health care
professionals in the United States, with 90% of Americans
living within 5 miles of a community pharmacy.9 With
increasing legalization of both recreational and MC, patients,
consumers, and health- care professionals are likely to rely on
pharmacists for knowledge on cannabis’s efficacy, safety,
dosing, and drug interactions. Surveys of pharmacy students
have shown more than half of pharmacy students support MC
legalization, with a recent survey showing an 85% acceptance
rates in 2018 at a private pharmacy school in the Midwest.10,11
Some states have moved to include pharmacists in the
dispensing of MC in some capacity.2 Connecticut, Minnesota,
New York, and Pennsylvania require a pharmacist or a health
care professional, depending on the state, to be onsite at MC
dispensaries, whereas Arkansas requires dispensaries to
appoint a pharmacist consultant.12-14 In Louisiana, the Board of
Pharmacy is required to establish standards for packaging,
labeling, and dispensing of MC at Marijuana Pharmacies.15 In
addition, CBD supplements are being sold at pharmacies
nationwide.16 Given the accessibility of pharmacists and theincreasing availability of both medical and recreational
cannabis, pharmacists should understand the impact that
cannabis can have on an individual’s illnesses and concomitant
drug therapy. Pharmacists are being asked about cannabis, and
CBD, even if their state does not require involvement in its
dispensing. Furthermore, pharmacists should be gathering
information about the use of cannabis to identify any impact
on the patient’s pharmacotherapy regimen consistent with the
American Pharmacist Association (APhA) position statement.17
The American Society of Health System Pharmacist (ASHP)
and APhA have developed position statements regarding
MC.17,18 Both organizations support the education of pharma-
cists to respond to patient and clinician questions. However,
surveys of pharmacists and pharmacy students have shown
that more training and education is necessary to answer
clinical questions on MC.10,11,19-21
Three published studies have assessed pharmacy student
knowledge about MC.10,11,19 Two studies were conducted at
Midwestern pharmacy schools where MC was illegal, in 2011
and 2017.10,11 Both studies surveyed first through third year
pharmacy students and found that most students were not
able to correctly identify conditions for which MC is generally
permitted. Berlekamp et al. also surveyed pharmacy students’
knowledge and attitudes about cannabis but in a state where
MC became legally available in 2017.19 In their survey of
pharmacy students, the authors also found low knowledge
about MC regarding indications, adverse effects, and cyto-
chrome P450 interactions. All authors concluded that there
was a knowledge gap for pharmacy students regarding MC at
their institutions.
Objectives
In the present study, the authors sought to update the re-
sults of the previous Moeller and Woods study conducted in
2011 by expanding the survey to include pharmacy schools
nationally. In addition, the authors sought to compare
knowledge and perceptions of pharmacy students in schools
that are located in states with and without MC laws.
Methods
An anonymous online survey (Qualtrics, Provo, UT)
regarding pharmacy students’ perceptions and knowledge of
MC was distributed to select schools of pharmacy across the
United States in early fall 2018. Equal numbers of schools
were selected based on geographical regions (Southeast,
Northeast, Midwest, Southwest, West), private versus public
universities, and the state’s legal status of MC, to provide
balanced representation. Pharmacy schools’ deans at 44 in-
stitutions were first sent an e-mail asking them to distribute
the survey among their first through fourth-year pharmacy
students. Reminder e-mails were sent mid-fall semester, and
the survey closed at the end of the fall semester. At the time
of survey distribution, 31 states and DC had legalized MC,
and 9 states and DC had approved recreational cannabis. The
survey was voluntary and was approved by the Human
Subjects Committees at The University of Kansas and Bel-
mont University.
The survey was adopted and updated from the lead au-
thor’s survey distributed to pharmacy students at a Midwest219
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SCIENCE AND PRACTICEpublic university in 2011 where MC was illegal. At the time of
the original survey development, only 14 states had approved
MC. The previous survey has been adapted for use and cited in
other health care professional surveys.10,11,22
The current survey consisted of 3 sections: (1) de-
mographics and personal factors, (2) knowledge assessment of
indications and adverse effects of MC, and (3) perceptions
assessment (5-point Likert scale questions). The survey in-
strument is in Appendix 1, available on JAPhA.org as supple-
mental content.
Demographic information collected included age, gender,
year in pharmacy school and pharmacy school information
(public vs. private, and state). Personal factors addressed
included family and personal history of substance abuse, his-
tory of cannabis use, and personal connection to someone
using MC. Students were also asked if they had received any
formal education on MC as part of the required curriculum.
The second section of the survey assessed students’
knowledge of qualifying conditions and adverse effects
regarding MC. Students were provided with a list of 19 con-
ditions and were asked the following question “States vary
regarding qualified conditions for medical use of marijuana.
From the list below, please select which of the following are
common uses for medical marijuana.” Four of the conditions
were considered false or incorrect (hypertension, depression,
schizophrenia, and sleep apnea). The correct uses were
selected from a list of qualifying conditions in legal states at
time of survey development. Of the 15 correct answers, the
majority of qualifying conditions were approved in more than
three-fourths of the states. All indications were approved in at
least 4 or more states. Students were next asked to select
potential adverse effects from a list of 21 symptoms with 5
incorrect answers (water retention, muscle aches, con-
stipation, hypoglycemia, and increased bleeding).
The last section of the survey assessed student’s percep-
tions and confidence in answering questions regarding med-
ical and recreational cannabis. Students were presented with
31 Likert scale questions (1 ¼ strongly disagree and 5 ¼
strongly agree). For analysis, responses were grouped into
agree/strongly agree and all other responses to produce a
dichotomous variable.
Differences between students attending pharmacy schools
in states with legalized MC and those attending schools in
states without MC were compared. Select studentTable 1
Demographics
Demographics Total
Age median (IQR) 23 (22e25)
Gender, n (%) (n ¼ 505)
Female 345 (68.3)
Male 160 (31.7)





Family history of substance abuse, n (%) 180 (30.3) (n ¼ 595)
Personal history of substance abuse, n (%) 26 (4.4) (n ¼ 595)
Knows someone who used marijuana, n (%) 271 (53.7) (n ¼ 505)
Personally used marijuana, n (%) 264 (52.7) (n ¼ 501)
Received in-depth discussion of MC, n (%) 75 (14.9) (n ¼ 503)
Abbreviations used: IQR, interquartile range; MC, medical cannabis.
220demographics, training regarding cannabis, and perceptions
about cannabis were compared using chi-square. Student
knowledge of MC indications and adverse effects were treated
as quizzes for analysis, and both the percentage of questions
correct and whether or not students passed the quizzes
( 70%) were also evaluated. Median percentage correct was
compared using Mann-Whitney U test, and number of stu-
dents passing was assessed using chi-square. A subanalysis
was run comparing quiz results between students who re-
ported having an in-depth discussion regarding MC in phar-
macy school and those who did not, to see if in-depth
discussions improved knowledge. In addition, the authors
compared quiz results of first- and second-year professional
students (P1/P2) to third- and fourth-year professional stu-
dents (P3/P4). Statistical analyses were performed using SPSS
25 (IBM, Armonk, NY) with an a priori alpha at 0.05.
Results
Of the 44 schools that were contacted, three schools replied
they would not distribute the survey based on school policy.
Students from 10 states filled out the survey. Seven states
(Florida, Illinois, Massachusetts, New Mexico, New York, Ohio,
and West Virginia) had MC laws, and 3 states (Idaho, Kansas,
and Tennessee) were without MC laws. Because the survey
was distributed to multiple schools in states that responded (3
in Florida, 2 in Illinois, 2 in Idaho, 2 inMassachusetts, 2 in Ohio,
and 2 in Tennessee), the authors were unable to determine the
number of schools that responded. Based on the number of
schools that were sent the survey and the states that respon-
ded, a maximum of 17 schools of pharmacy may have been
surveyed. However, in states where multiple schools were
surveyed, the authors were unable to determine if more than 1
school filled out the survey, so a minimum of 10 schools may
have been surveyed.
A total of 629 students accessed the survey, and of those,
505 (80.3%) responded to most or all of the items. De-
mographics for students enrolled in pharmacy schools in
states with MC and those in states without MC are shown in
Table 1 and were not significantly different. Only 14.9% (29 of
195 and 46 of 308 students, respectively) of students in both
groups reported having an in-depth discussion of MC as part of
their core curriculum. Furthermore, 94.9% (186/196) of the
students in the MC states, and 96.1% (298/310) of the studentsSchool in states with MC School in states without MC P value
23 (22e26) 23 (22e25)
(n ¼ 196) (n ¼ 309)
135 (68.9) 210 (68)
61 (31.1) 99 (32)
(n ¼ 196) (n ¼ 309)
53 (27) 59 (19.1)
51 (26) 67 (21.7)
43 (21.9) 90 (29.1)
49 (25) 93 (30.1)
68 (28.2) (n ¼ 241) 112 (31.6) (n ¼ 354) 0.372
12 (5) (n ¼ 241) 14 (4) (n ¼ 354) 0.548
113 (57.9) (n ¼ 195) 158 (51) (n ¼ 310) 0.126
102 (52.6) (n ¼ 194) 162 (52.8) (n ¼ 307) 0.967











































































































































































































































































































































































































































































































































Knowledge and perceptions about medical cannabis
SCIENCE AND PRACTICEin the non-MC states thought faculty should include infor-
mation about MC in their classes (P ¼ 0.508).
Student knowledge of indications and adverse effects are
shown in Table 2. Students in schools whose state has MC
legalization did not have a higher percentage of students
scoring greater than 70% correct on indications comparedwith
students in states without MC (14.8% vs. 15.9; P ¼ 0.748,
respectively). Further, students in MC states did not score
greater than 70% more than students in states without MC
when looking at the side effects (6.1% vs 7.4%; P ¼ 0.569,
respectively). A subanalysis of those who received in-depth
discussions versus those who did not is shown in Table 2,
and no differences were seen between groups. However, when
we looked at year in pharmacy school, the P3/P4 students
compared with P1/P2 students were more likely to pass both
the indications (20.4% vs. 13.1 %; P ¼ 0.031, respectively) and
adverse effect quizzes (9.1% vs. 4.4%; P ¼ 0.038, respectively).
Perceptions about cannabis (medical, recreational, and
confidence in providing drug information on MC) are pre-
sented in Table 3. Students in states with MC laws were sta-
tistically more likely to think MC was safe in pregnancy (P ¼
0.008), has fewer negative health effects than prescription
medications (P¼ 0.01), and less likely to impair one’s ability to
drive (P ¼ 0.032).Discussion
To the authors’ knowledge, this is the first national study to
assess differences in knowledge and perceptions of MC of
pharmacy students studying in states where MC is legal or
illegal. Overall, the study found minimal differences in
knowledge and perceptions of pharmacy students regardless
of state MC laws. Moreover, this study continues to show that
pharmacy students lack knowledge of MC.
Over 90% of all pharmacy students surveyed favored MC
legalization and nearly three-fourths of students felt phar-
macists should be involved in the dispensing process of MC.
This high rate of students favoring MC legalization is consis-
tent with a 2017 survey of pharmacy students in Iowa (illegal
MC state).10 However, it is significantly higher than a 2011
study in which only 59% favored legalization.11
Despite the strong support for pharmacist involvement,
less than half of the students surveyed, irrespective of their
state cannabis laws, felt knowledgeable concerning efficacy,
drug interactions, and providing drug information on MC.
This is also evident in the knowledge section of the current
survey where the median percent correct score in both the
approved indications and adverse effect sections were less
than 60%, indicating a failing score for most students.
Regarding passing scores, only about 15% of the students in
states with legalized MC scored higher than 70% for in-
dications compared with about 16% for students who studied
in states where MC was illegal (P ¼ 0.748). Students in states
with legalized MC were also no more likely to score a passing
grade on the adverse effects quiz (6.1%) compared with
students in states with illegal MC (7.4%; P ¼ 0.569). Our re-
sults are consistent with Berlekamp et al. study from Ohio, a
legal MC state, which found pharmacy students’ correct re-
sponses ranged between 50% to 60% for all knowledge
questions.19221
Table 3
Attitudes toward cannabis (agree or strongly agree)
Perception questions regarding cannabis School in state
with MC, n (%)
School in state
without MC, n (%)
P value
In my opinion, marijuana should be legalized for medicinal uses. 176 (89.8) 279 (90.3) 0.856
In my opinion, all clinicians with prescribing rights (e.g., advanced nurse practitioners,
physician assistants) should be able to prescribe MMJ.
106 (54.1) 149 (48.2) 0.199
In my opinion, I feel pharmacists should be involved in the dispensing process for MMJ. 144 (73.8) 223 (72.2) 0.680
I feel that marijuana is safe when used responsibly for medical use. 158 (80.6) 258 (83.5) 0.407
I feel MMJ should be available for use in children. 83 (42.3) 117 (38.2) 0.359
I feel MMJ is safe to use in pregnancy and lactation. 20 (10.3) 13 (4.2) 0.008a
I feel that marijuana can be detrimental to one’s health for medical use. 40 (20.4) 61 (19.7) 0.855
I feel that MMJ is often abused. 88 (44.9) 147 (47.6) 0.557
I feel that legalizing MMJ would cause crimes rates to increase. 14 (7.2) 20 (6.5) 0.758
I feel that legalizing MMJ would cause more people to use marijuana in non-medical ways. 96 (49) 160 (51.8) 0.54
I consider myself knowledgeable on the subject of MMJ. 60 (30.6) 85 (27.5) 0.452
I understand the difference between delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD). 149 (76) 242 (78.3) 0.547
I feel comfortable answering questions from my patients about the efficacy of MMJ. 62 (31.6) 91 (29.5) 0.619
I feel comfortable answering questions from my patients about drug interactions with MMJ. 28 (14.3) 40 (12.9) 0.667
I feel that MMJ is safe to use with prescription medications. 47 (24) 92 (29.8) 0.155
I feel that MMJ is safe to use with non-prescription medications. 54 (27.6) 88 (28.5) 0.821
I feel that MMJ has been adequately studied by scientists. 38 (19.4) 55 (17.8) 0.654
I feel that the majority of people who support the legalization of MMJ are drug abusers. 15 (7.7) 24 (7.8) 0.955
If I had to make a decision today about legalization of MM, I would be in
favor of doctor prescribed MMJ.
166 (84.7) 270 (87.7) 0.342
I feel that our government has adequate resources to regulate the use of MMJ. 123 (62.8) 176 (57.1) 0.211
In my opinion, marijuana should be legalized for the general population. 122 (62.2) 189 (61.4) 0.843
I feel that marijuana is a gateway drug. 49 (25.1) 71 (23) 0.581
I feel that marijuana is safe when used responsibly for recreational use. 117 (59.7) 192 (62.5) 0.522
I feel that recreational use of marijuana can be detrimental to one’s health. 81 (41.3) 131 (42.5) 0.789
I feel that legalizing marijuana for any use would cause crime rates to increase. 15 (7.7) 32 (10.4) 0.308
I feel marijuana has fewer negative health effects than alcohol. 136 (69.4) 226 (73.1) 0.362
I feel users can become addicted to marijuana. 101 (51.5) 175 (56.6) 0.262
I feel marijuana has fewer negative health effects than tobacco. 133 (68.2) 230 (74.4) 0.129
I feel marijuana has fewer negative health effects than prescription opiate mediations. 164 (83.7) 245 (79.8) 0.278
I feel marijuana has fewer negative health effects than prescription medications. 88 (45.1) 104 (33.7) 0.01a
I feel marijuana can impair one’s ability to drive. 162 (83.1) 277 (89.6) 0.032a
Abbreviations used: MC, medical cannabis; MMJ, medical marijuana.
a Statistically significant, chi-square test.
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SCIENCE AND PRACTICEWith respect to indications, this study found that students
were most likely to know that cancer (69%), pain disorders
(63.1%), and epilepsy (62.8%) were approved indications for
MC. This is similar to Caligiuri et al. study in which most
pharmacy students at a pharmacy school in Iowa, an illegal MC
state, correctly identified cancer (74%), epilepsy (74%), and
migraines (55%) as correct indications.10 However, results from
the current study differ from our previous study conducted in
2011 where the top correct indications were cancer (91%) and
glaucoma (52%). At the time of the 2011 study survey, only 11%
indicated epilepsy as an indication for cannabis. This sharp
knowledge change is likely owing to the recent approval of
CBD for seizures and extensive media coverage on cannabis
use for seizures. The decline in knowledge for use in cancer
(69% vs. 91%) may be due to the previous survey conducted at
only 1 institution where MC may have been emphasized in
oncology sections of the curriculum compared with this study
that surveyed multiple pharmacy schools.
Most pharmacy students in this survey, regardless of their
state’s legal status, considered cannabis to be safe for medical
use (>80%). The majority of pharmacy students thought that
cannabis had fewer adverse health effects than alcohol, to-
bacco, and opioids. This is consistent with a 2017 survey of
family medicine physicians where 85% of medical residents
and 67% of faculty physicians expressed low concern for222cannabis safety (respondents rated items as either low, me-
dium or high concern) and low-medium concern for canna-
bis’s “potential for addiction or its psychoactive problems.”23
This trend in safety concern was also shown in a 2014 survey
of health care professionals practicing in Washington (a MC
state), where only 40% of clinicians viewed MC having signif-
icant physical health concerns, and 45% of clinicians felt MC
could result in serious mental health adverse effects.24 These
studies contrast a 2011 survey of Colorado physicians
(MC state) in which greater than 60% of physicians agreed MC
had a significant physical and mental health risk.25 Based on
our study and other studies, it appears that health care pro-
fessionals, including pharmacy students, perceptions have
followed those of the general public. Felson et al. sought to
identify why public opinions have changed dramatically since
the 1980s.26 The authors found there are multiple factors that
may have led the change in public opinion, including a
decrease in religious affiliation, a decline in punitiveness, and a
shift in media coverage. It is imperative that pharmacists be
equipped with the best information possible about the safety
and efficacy of MC rather than providing information based on
public opinion or media coverage.
Mental health risks and addiction are evolving concerns for
MC. According to the National Academies of Science review,
there is substantial evidence of a statistical association
Knowledge and perceptions about medical cannabis
SCIENCE AND PRACTICEbetween cannabis use and the development of schizophrenia
or other psychoses.5 In addition, cannabis has been associated
with depressive symptoms, an increase in suicidal thoughts,
and worsening of depression in patients with a diagnosis of
depression.27-30 Nonetheless, less than a quarter of the stu-
dents in our study listed depression and risk for schizophrenia
as an adverse effect. More than 50% of our respondents agreed
that cannabis can be addictive. This is lower than surveys of
medical students and physicians, which rated the potential for
addiction greater than 80%.25,31 The National Academies of
Science review found that there is substantial evidence of a
statistical association between increases in cannabis use fre-
quency and the progression to problem cannabis use.5 Less
than 14% of students in our survey were comfortable
answering questions from patients about drug interactions
with MC. Likewise, almost a third of students felt that MC is
safe to use with nonprescription and prescriptionmedications.
There is the potential for significant drug-drug interactions
with THC inhibiting CYP2C9 and 3A4, and smoked cannabis
inducing CYP1A2.32 In addition, there is the potential for sig-
nificant pharmacodynamic interactions including additive
sedation/cognitive/psychomotor impairment with concomi-
tant central nervous system depressants and cardiac toxicity
including hypertension and tachycardia with sympathomi-
metics.33 There is still limited availability of information
regarding all the potential drug interactions with MC, thereby
suggesting a need for continued research and education on
this topic which is of particular importance for pharmacists.
Nearly all students in this survey indicated that they felt
instruction on MC was imperative in the pharmacy school
curriculum. However, only 15% indicated they received some
formalized instruction on MC. This differs from 2 studies that
surveyed educators on pharmacy school’s curriculum. These
studies both reported that 62% of pharmacy schools included
some MC discussion into the curriculum most commonly
regarding indications, adverse effects, and legal status.19,34 In
both these surveys, response rates were low and did not
indicate the depth of instruction (e.g., number of hours
taught). The current study, however, surveyed pharmacy stu-
dents at different stages in the curriculum, and many may not
have received MC education at the time of the survey.
This study had limitations. The survey was sent to several
schools of pharmacy that did not indicate whether or not the
survey would be distributed, so it cannot be determined how
many students actually received the survey. When selecting a
balanced representation of schools to distribute the survey, the
authors did not take in account timing of state legalization or
state’s recreational status. Students from 7 states that had
approved MC completed the survey, with West Virginia last
approving MC in 2017. Of the 7 states, Massachusetts was the
only state at time of survey distribution that had approved
recreational cannabis in 2016, although the first dispensary
opened in 2018 during survey distribution. Studies have
shown that commercialization of cannabis is correlated with a
decreased risk perception.35 Consequently, students’ percep-
tions may have been influenced with changing legal status.
Furthermore, schools in states where pharmacists have a
specified role in MC distribution were solicited (Arkansas,
Connecticut, Minnesota, New York, and Pennsylvania); how-
ever, no responses were received from students in those states.
It is possible that students in these states may have moreeducation in MC and could affect the results of our study.
Further studies with students in these states are imperative.
Another limitation of this study is that qualifying condi-
tions or indications for MC differ from state to state. The au-
thors looked at general knowledge across states regarding
indications and did not ask or separate out state-specific in-
dications. Students in states where MC is legal may be more
familiar with their state-approved uses as opposed to other
states’ indications. However, the authors chose the most
common qualifying conditions to include in the survey.
Whereas 629 students accessed the survey, not all of them
completed the entire questionnaire, which may reflect some
response bias owing to the topic being surveyed. Those
questionnaires with missing data were still included in the
analyses but may limit interpretation of the results. Further-
more, it is not possible to verify the number of schools that
distributed the survey to students; so neither can the exact
response rate be determined nor can the characteristics of
nonresponders be examined. Studies have shown poorer
response rates with Web-based surveys compared with paper
surveys administered through the mail.36 There were also
some student responses to the demographic questions that
appeared incorrect, such as students indicating their univer-
sity was private when it was actually public, and indicating
attending school in a state where the survey was not
distributed.Conclusion
Although students feel pharmacists should be involved in
the dispensing process of MC, this study continues to highlight
that pharmacy students are not prepared to recommend,
counsel, and interpret drug interactions related to MC. The
Accreditation Standards for Pharmacy Education should
address this knowledge gap and lack of formal training in
pharmacy schools’ curriculum. As pharmacists, we are
considered the drug experts and will be asked questions
regarding efficacy, safety, and drug interactions. It is impera-
tive that pharmacy students and pharmacists be able to
engage in an educated discussion with patients and other
health care providers about MC and CBD to gain their respect
and provide useful education that will be followed.References
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SCIENCE AND PRACTICEAppendix 1
Q1 e Information on University IRB & Consent to partici-
pate - I wish to continue
 Yes (1)
 No (2)
Q2 What is your age?
_____________
Skip To: End of Survey If What is your age? < 18
Q3 In what state is your pharmacy school located?
Q4What is your state or US Territory of permanent residence?
Q5 What is your religious affiliation?
Q6 Do you have a family history of substance abuse?
 Yes (1)
 No (2)
Q7 Do you personally have a history of substance abuse?
 Yes (1)
 No (2)
Q8 Is your pharmacy school a public or private institution?
 Public (1)
 Private (2)
Q9 Is medical marijuana approved for use in the state
where you attend pharmacy school?
 Yes (1)
 No (2)
Q10 Is medical marijuana approved for use in the state that
you would identify as your primary state of residence?
 Yes (1)
 No (2)








Skip To: Q14 If Do you think marijuana should be legalized
for recreational use? ¼ No
Q13 Do you feel that the main reason marijuana should be




Q14 How many states allow the use of medical marijuana
for authorized indications?
 Less than 10 (1)
 10-20 (2) 21-30 (3)
 31-40 (4)
 41-50 (5)
Q15 How many states allow the use of recreational
marijuana?





Q16 States vary regarding qualified conditions for medi-
cal use of marijuana. From the list below, please select
which of the following are common uses for medical
marijuana.
, Agitation in Alzheimer's Disease (1)
, ALS (Lou-Gehrig's Disease) (2)
, Cancer (3)




, Hepatitis C (8)
, Pain Disorders (9)
, HIV-AIDS (10)
, PTSD (11)
, Multiple Sclerosis (12)
, Depression (13)
, Nausea/Vomiting (14)
, Parkinson's Disease (15)
, Schizophrenia (16)
, Tourette's Syndrome (17)
, Sleep Apnea (18)
, Cachexia (low body weight) (19)
Q17 For each adverse event or effects listed below, please
select which adverse event or effect is associated with
marijuana.
, Water retention (1)
, Anxiety (2)
, Blurred vision (3)






, Increased bleeding (10)
, Insomnia (11)
, Lung cancer (12)
, Memory impairment (13)
, Nausea (14)
, Dependence/ withdrawal (15)
, Paranoia (16)
, Seizures (17)
, Impaired brain development in adolescents (18)
, Increased risk for schizophrenia (19)
, Worsening asthma (20)
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224.e28 Please indicate how strongly you agree or disagree
th each of the following statements using the following
le1¼Strongly Disagree 2¼Disagree 3¼Neutral
4¼Agree 5¼Strongly AgreeStrongly
Disagree (1)




y opinion, marijuana should be legalized for
edicinal uses. (1)
B B B B B
y opinion, all clinicians with prescribing rights (e.g.
vanced nurse practitioners, physician assistants)
ould be able to prescribe medical marijuana. (2)
B B B B B
y opinion, I feel pharmacists should be involved in
e dispensing process for medical marijuana. (3)
B B B B B
l that marijuana is safe when used responsibly for
edical use. (4)
B B B B B
l medical marijuana should be available for use in
ildren. (5)
l medical marijuana is safe to use in pregnancy and
ctation. (6)
B B B B B
l that marijuana can be detrimental to one’s health
r medical use. (7)
B B B B B
l that medical marijuana is often abused. (8) B B B B B
l that legalizing medical marijuana would cause
imes rates to increase. (9)
B B B B B
l that legalizing medical marijuana would cause
ore people to use marijuana in non-medical ways.
0)
B B B B B
sider myself knowledgeable on the subject of
edical marijuana. (11)
B B B B B
erstand the difference between delta-9
trahydrocannabinol (THC) and cannabidiol (CBD).
2)
B B B B B
l comfortable answering questions from my
tients about the efficacy of medical marijuana. (13)
B B B B B
l comfortable answering questions from my
tients about drug interactions with medical
arijuana. (14)
B B B B B
l that medical marijuana is safe to use with
escription medications. (15)
B B B B B
l that medical marijuana is safe to use with non-
escription medications. (16)
l that medical marijuana has been adequately
udied by scientists. (17)
B B B B B
l that the majority of people who support the
galization of medical marijuana are drug abusers.
8)
B B B B B
ad to make a decision today about legalization of
edical marijuana, I would be in favor of doctor
escribed medical marijuana. (19)
l that our government has adequate resources to
gulate the use of medical marijuana. (20)
B B B B B
y opinion, marijuana should be legalized for the
neral population. (21)
B B B B B
l that marijuana is a gateway drug. (22) B B B B
l that marijuana is safe when used responsibly for
creational use. (23)
B B B B B
l that recreational use of marijuana can be
trimental to one’s health. (24)
B B B B B
l that legalizing marijuana for any use would cause
ime rates to increase. (25)
B B B B B
l marijuana has fewer negative health effects than
cohol. (26)
B B B B B
l users can become addicted to marijuana. (27) B B B B B
l marijuana has fewer negative health effects than
bacco. (28)








I feel marijuana has fewer negative health effects than
prescription opiate mediations. (29)
B B B B B
I feel marijuana has fewer negative health effects than
prescription medications. (30)
B B B B B
I feel marijuana can impair one’s ability to drive. (31) B B B B B
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Q21 Does your school of pharmacy include in-depth dis-
cussion of medical marijuana in the core curriculum like
other drug classes that you are taught?
 Yes (1)
 No (2)
Q22 Do you feel that professors should include information
about medical marijuana in your classes?
 Yes (1)
 No (2)Q23 Please select the gender you identify with:
 Male (1)
 Female (2)





Q25 During your education/training, have you received any
specific education about medical marijuana?
 Yes (1)
 No (2)
Skip To: Q26 If During your education/training, have you
received any specific education about medical
marijuana? ¼ Yes
Q26 Please briefly describe where you learned about
medical marijuana:
________________
Q27 Thank you for your participation224.e3
